Digoxin use and the risk of breast cancer in women

Journal of Clinical Oncology

Volumn 29, Issue 16, 2011, Pages 2165-2170

  Biggar, Robert J ^a,b   Wohlfahrt, Jan ^a,b   Oudin, Anna ^a,b   Hjuler, Thomas ^a,b   Melbye, Mads ^a,b  

^a STATENS SERUM INSTITUT   (Denmark)

^b UMEÅ UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANGINA PECTORIS AGENT; DIGOXIN; ESTROGEN RECEPTOR; GLYCERYL TRINITRATE; ISOSORBIDE DINITRATE; ISOSORBIDE MONONITRATE; NICORANDIL;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER REGISTRY; CANCER RISK; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK FACTOR;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARDIOTONIC AGENTS; DIGOXIN; FEMALE; HUMANS; INCIDENCE; MIDDLE AGED; RECEPTORS, ESTROGEN; RISK FACTORS; YOUNG ADULT;

EID: 79957962089     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.32.8146     Document Type: Article

References (35)

1. McDonough AA, Velotta JB, Schwinger RH, et al: The cardiac sodium pump: Structure and function. Basic Res Cardiol 97:I19-24, 2002 (suppl 1)
2. Rifka SM, Pita JC Jr, Loriaux DL: Mechanism of interaction of digitalis with estradiol binding sites in rat uteri. Endocrinology 99:1091-1096, 1976
3. Rifka SM, Pita JC, Vigersky RA, et al: Interaction of digitalis and spironolactone with human sex steroid receptors. J Clin Endocrinol Metab 46:338-344, 1978 (Pubitemid 8312337)
4. Braunstein GD: Gynecomastia. N Engl J Med 328:490-495, 1993
5. Lenfant-Pejovic MH, Mlika-Cabanne N, Bouchardy C, et al: Risk factors for male breast cancer: A Franco-Swiss case-control study. Int J Cancer 45:661-665, 1990 (Pubitemid 20146125)
6. Ewertz M, Holmberg L, Tretli S, et al: Risk factors for male breast cancer-a case-control study from Scandinavia. Acta Oncol 40:467-471, 2001 (Pubitemid 32682030)
7. Stenkvist B, Pengtsson E, Dahlqvist B, et al: Cardiac glycosides and breast cancer, revisited. N Engl J Med 306:484, 1982 (Pubitemid 12171682)
8. Friedman GD: Digitalis and breast cancer. Lancet 2:875, 1984
9. Haux J, Klepp O, Spigset O, et al: Digitoxin medication and cancer; case control and internal dose-response studies. BMC Cancer 1:11, 2001
10. Ahern TP, Lash TL, Sørensen HT, et al: Digoxin treatment is associated with an increased incidence of breast cancer: A population-based case control study. Breast Cancer Res 10:R102, 2008
11. Key TJ, Allen NE: Hormones and breast cancer. IARC Sci Publ 156:273-276, 2001
12. Schairer C, Byrne C, Keyl PM, et al: Menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer (United States). Cancer Causes Control 5:491-500, 1994 (Pubitemid 24335711)
13. Colditz GA, Hankinson SE, Hunter DJ, et al: The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 332:1589-1593, 1995
14. Collaborative Group on Hormonal Factors in Breast Cancer: Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350:1047-1059, 1997
15. Women's Health Initiative Investigators: Risk and benefits of estrogen plus progestin use in healthy postmenopausal women. JAMA 288:321-333, 2002
16. Million Women Health Study Collaborators: Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362:419-427, 2003
17. Chlebowski RT, Kuller LH, Prentice RL, et al: Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 360:573-587, 2009
18. Schairer C, Lubin J, Troisi R, et al: Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 283:485-491, 2000 (Pubitemid 30062864)
19. Storm HH, Michelsen EV, Clemmensen IH, et al: The Danish Cancer Registry-history, content, quality, and use. Dan Med Bull 44:535-539, 1997
20. Gaist D, Sorensen HT, Hallas J: The Danish prescription registries. Dan Med Bull 44:445-448, 1997 (Pubitemid 27382061)
21. Fritz A, Percy C, Jack A, et al (eds): World Health Organization: International Classification of Diseases for Oncology (ed 3). Geneva, Switzerland, World Health Organization, 2000
22. Talman MM, Rasmussen BB, Andersen J, et al: Estrogen receptor analyses in the Danish Breast Cancer Cooperative Group: History, methods, prognosis and clinical implications. Acta Oncol 47:789-794, 2008 (Pubitemid 351878445)
23. Preston DL: Poisson regression in epidemiology, in Armitage P, Colton T (eds): Encyclopedia of Biostatistics, volume 6 (ed 2). New York, NY, John Wiley and Sons, 2005, pp 4124-4127
24. Wohlfahrt J, Andersen PK, Melbye M: Multivariate competing risks. Stat Med 18:1023-1030, 1999 (Pubitemid 29213722)
25. Cleary MP, Grossmann ME, Ray A: Effect of obesity on breast cancer development. Vet Pathol 47:202-213, 2010
26. Banks E, Canfell K: Hormone therapy risks and benefits: The Women's Health Initiative findings and the postmenopausal estrogen timing hypothesis. Am J Epidemiol 170:24-28, 2009
27. Wells CA, Sloane JP, Coleman D, et al: Consistency of staining and reporting of oestrogen receptor immunocytochemistry within the European Union: An inter-laboratory study. Virchows Arch 445:119-128, 2004
28. Missmer SA, Eliassen AH, Barbieri RL, et al: Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among post-menopausal women. J Natl Cancer Inst 96:1856-1865, 2004
29. Schiff R, Selever J, Fuqua SAW: The importance of estrogen receptors in breast cancer, in Pasqualini JR (ed): Breast Cancer: Prognosis, Treatment and Prevention. New York, NY, Informa Healthcare, 2008, pp 83-111
30. Winnicka K, Bielawski K, Bielawska A: Cardiac glycosides in cancer research and cancer therapy. Acta Pol Pharm 63:109-115, 2006 (Pubitemid 351359766)
31. Newman RA, Yang P, Pawlus AD, et al: Cardiac glycosides as novel cancer therapeutic agents. Mol Interv 8:36-49, 2008 (Pubitemid 351398451)
32. Falconer IR, Beresford AM, Jones A, et al: Effect of digoxin on DNA synthesis and cell viability in human breast tumour tissue in organ culture. Chemotherapy 29:368-372, 1983 (Pubitemid 13044691)
33. Kometiani P, Liu L, Askari A: Digitalis-induced signaling by Na+/K+-ATPase in human breast cancer cells. Mol Pharmacol 67:929-936, 2005 (Pubitemid 40365340)
34. Chen JQ, Contreras RG, Wang R, et al: Sodium/ potasium ATPase (Na(+), K (+)-ATPase) and ouabain/related cardiac glycosides: A new paradigm for development of anti- breast cancer drugs? Breast Cancer Res Treat 96:1-15, 2006
35. Stenkvist B: Is digitalis a therapy for breast carcinoma? Oncol Rep 6:493-496, 1999